Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is celebrating the professionals delivering critical mental healthcare across the country in honor of Mental Health Awareness Month. Prioritizing mental health has never been more imperative than it is today. Since Neuronetics received FDA clearance in 2008 for its NeuroStar® Advanced Therapy transcranial magnetic stimulation (TMS) system — a proven, non-drug, non-invasive depression option for adults with Major Depressive Disorder (MDD) — the company has delivered more than 2.5 million treatments and has over 1,000 devices installed in doctors’ offices and hospitals in the United States.

MALVERN, Pa., May 05, 2020 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced preliminary first quarter 2020 revenue and provided a business update, including the actions it is taking in response to COVID-19. Depression is a debilitating condition that millions of patients suffer from worldwide, and for those undergoing or in need of treatment, we believe that TMS treatment is a medical necessity. As a result, the Company has taken steps to significantly reduce operating expenses and maintain the strength of our balance sheet.

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter 2020 financial and operating results prior to market open on Tuesday, May 5, 2020. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 5743759, approximately ten minutes prior to start time.

Whilst it may not be a huge deal, we thought it was good to see that the Neuronetics, Inc. (NASDAQ:STIM) Chief...

Neuronetics (STIM) delivered earnings and revenue surprises of -54.55% and -3.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Breakthrough Device Designation for the Company’s NeuroStar Advanced Therapy System for the treatment of bipolar depression.

MALVERN, Pa., March 03, 2020 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has been named a Top 10 Neurology Device Provider in 2020 by MedTech Outlook Magazine. The non-drug, non-invasive treatment uses magnetic pulses to stimulate areas of the brain that are underactive in depression.1,2 In an open-label clinical trial, 58 percent of patients responded to treatment and 37 percent experienced complete remission from depression.3 Treatment sessions can be performed in as little as 19 minutes* and it is covered by most major insurance providers, making it available and accessible to a growing patient population.

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has delivered over 2.5 million treatments with its NeuroStar® Advanced Therapy transcranial magnetic stimulation (TMS) system, in addition to recently exceeding 1,000 device installations in the United States.

Christopher Thatcher is stepping down effective immediately as president and CEO of Malvern medical technology developer Neuronetics after more than six years in the role. Shares of the company soared by nearly 22% in morning trading Friday to $3.30. Neuronetics (NASDAQ: STIM) had been down 65% year-to-date prior to Friday's opening.

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the Company and Christopher A. Thatcher, President and CEO of Neuronetics, have mutually agreed that Mr. Thatcher will cease serving as the Company’s President and Chief Executive Officer, effective immediately. In connection with his departure, Mr. Thatcher also resigned as a director of the Company’s Board of Directors (the “Board”).

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that its Board of Directors authorized the adoption of a limited duration rights plan (“Rights Plan”). The Board has adopted this Rights Plan following careful consideration, among other factors, of the COVID-19 pandemic’s disruptive impact on market stability and its effect on equity market valuations, including the recent dislocation of the Company’s stock price. The Board believes that the Company’s current trading level does not reflect Neuronetics’ inherent value or the potential of its products and strategy execution.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Fate Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter results) * Forty Seven Inc (NASDAQ: FTSV) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO)( announced an accelerated timeline for COVID-19 vaccine development) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 3) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * Akorn, Inc. (NASDAQ: AKRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) * Midatech Pharma PLC-ADR (NASDAQ: MTP)(began trading on a reverse split adjusted basis) * Mylan NV (NASDAQ: MYL) * Neuronetics Inc (NASDAQ: STIM)(announced its fourth-quarter results) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * SurModics, Inc. (NASDAQ: SRDX) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TransMedics Group Inc (NASDAQ: TMDX)(reported its fourth-quarter results) * VIVUS, Inc. (NASDAQ: VVUS) * Xeris Pharmaceuticals Inc (NASDAQ: XERS)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesStocks In Focus Takeda To Develop COVID-19 Treatments Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin to treat high-risk individuals with the viral infection. Hyperimmune globulins are plasma-derived therapies that had previously proven its efficacy in treating severe acute viral respiratory infections.The company added it is also studying its currently marketed and pipeline products to see whether they are effective treatments for infected patients.Separately, the company said it has completed its previously announced sale of portfolio of select products to STADA for $660 million.In pre-market trading Wednesday, Takeda shares were adding 3.94% to $18.20.Vir, Alnylam Expands Collaboration To Develop siRNA Therapies For COVID-19 Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion to their existing collaboration to include the development and commercialization of RNAi therapeutics against COVID-19. The agreement provides for Vir using Alnylam's recent advances in lung delivery of novel conjugates of siRNA along with its infectious disease expertise to develop one or some siRNAs to treat COVID-19 and other coronaviruses as well.In premarket trading Wednesday, Vir share were rallying 14.72% to $47 and Alnylam was edging up 0.41% to $111.88.Mallinckrodt Reports Positive Outcome Analysis of Acthar Gel In Immune-mediated Diseases Mallinckrodt PLC (NYSE: MNK) announced findings from a retrospective medical record analysis, which assessed practice patterns and outcomes of Acthar Gel in the treatment of immune-mediated diseases rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis, which showed across all the three patient populations, symptoms improved with Acthar Gel.In premarket trading Wednesday, the shares were advancing 7.99% $3.38.Acadia's Rett Syndrome Investigational Drug Gets Rare Pediatric Designation ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharma said the FDA has granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.Upon approval of a product with the designation, the sponsor is eligible to receive a Priority Review Voucher, which can be used to obtain FDA approval of an NDA for another product in an expedited period of six months.Acadia shares were up 2.41% to $42.99 in after-hours trading.Morphosys' Licensing Agreement With Incyte For Lymphoma Drug Gets Antitrust Clearance Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said their joint collaboration and license agreement for further development and global commercialization of Morphosys' investigational compound tafasitamab has received antitrust clearance and becomes effective Tuesday.The regulatory milestone triggers a $750 million upfront payment by Incyte to Morphosys, and also Incyte's equity investment of $150 million into MorphoSys within the defined timelines.The PDUFA date for the BLA for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma is Aug. 30.Ultragenyx CFO To Step Down Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) said Shalini Sharp will step down as CFO and EVP, effective Sept. 2. The company said it will initiate a search for a successor.Exact Sciences Buys Two Cancer Diagnostics Companies Exact Sciences said it has completed its acquisition of Paradigm Diagnostics and Viomics, two privately held companies, which provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery.View more earnings on TAKThe company expects the acquisition to extend its lab testing and research and development capabilities.J&J Makes Regulatory Submission For Approval of Multiple Sclerosis Drug In Europe Johnson & Johnson's (NYSE: JNJ) Janssen unit announced it submitted a Marketing Authorization Application to EMA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Earnings DURECT Corporation (NASDAQ: DRRX) reported fourth-quarter net revenues of $10.69 million compared to $3.63 million last year. The net loss per share narrowed from 5 cents to 2 cents, in line with the consensus estimate.The stock jumped 12.21% to $1.93 in after-hours trading.Menlo Therapeutics Inc's (NASDAQ: MNLO), which has agreed to be bought by Foamix Pharmaceuticals Ltd (NASDAQ: FOMX), reported a wider loss of 89 cents per share compared to the year-ago loss of 76 cents per share and the consensus loss estimate of 83 cents per share.Updating on the pending merger, Menlo said it expects it to close March 9.The stock jumped 23.64% to $3.40 in after-hours trading.Voyager Therapeutics Inc (NASDAQ: VYGR) reported fourth quarter revenues of $32.67 million compared to $2.01 million a year ago. The net loss per share narrowed from 77 cents to 34 cents. Analysts had estimated a loss of 81 cents per share. The company said it expects its cash reserves as well as receivables to be sufficient to meet its projected operating expenses and capex into mid-2022.The stock gained 6.22% to $12.30 in after-hours trading.Vivus reported fourth-quarter total revenues of $17.25 million and a loss of 61 cents per share, narrower than the 68 cents per share loss expected by analysts.The stock rose 8.98% to $1.82 in after-hours trading.Offerings Zogenix, Inc. (NASDAQ: ZGNX) said it has priced its underwritten public offering of 8.52 million shares at $23.50 per share. The company expects to raise gross proceeds of $200.2 million from the offering. The offering is expected to close on or about March 6.The company said it expects to use the net proceeds for the potential commercialization of Fintepla for the treatment of Dravet syndrome, among other things.The stock fell 3.69% to $24 in after-hours trading.On The Radar Earnings * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (before the market open) * Recro Pharma Inc (NASDAQ: REPH) (before the market open) * PPD Inc (NASDAQ: PPD) (before the market open) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the close) * Orthopediatrics Corp (NASDAQ: KIDS) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close)See more from Benzinga * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 8) * Keros Therapeutics Inc (NASDAQ: KROS) (went public Wednesday and traded 25.5% higher to $20.08, up from the IPO price of $16)None of the NYSE- or Nasdaq-listed stocks hit 52-week lows Wednesday.Stocks In Focus Mesoblast To Evaluate Investigational Stem Cell Therapy For COVID-19 Respiratory Distress Australian biopharma Mesoblast limited (NASDAQ: MESO) said it will evaluate its allogenic mesenchymal stem cell product candidate remestemcel-L in a randomized, placebo-controlled Phase 2/3 trial in 240 patients with acute respiratory distress syndrome caused by coronavirus infection.The trial will be conducted as a public-private partnership in collaboration with the Cardiothoracic Trials Network established by the U.S. NIH's National Heart, Lung and Blood Institute.The company has an IND application for the therapy from the FDA for use in the treatment of patients with COVID-19 ARDS.The stock was trading 32.34% higher at $7.57 in Thursday's premarket session. Pfizer's Combo Therapy For Colorectal Cancer Gets FDA Nod Pfizer Inc. (NYSE: PFE) announced FDA approval for Braftovi in combination with cetuximab for the treatment of adults with metastatic colorectal cancer with BRAFV600E mutation. The company noted that the approval was given based on results from the BEACON CRC trial.Pfizer shares were up 0.43% at $34.75 in the premarket session. Tiziana Develops Delivery Technology For Drug to Treat COVID-19 TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said it has developed an investigational new technology to treat COVID-19 infections that consists of direct delivery of anti-IL-6 receptor monoclonal antibodies into the lungs using a handheld inhaler or nebulizer.The development of the technology is a step toward expediting development of TZLS-501, a fully human anti-interleukin-6 receptor monoclonal antibody for treatment of patients infected with the coronavirus, according to Tiziana. The company said it has submitted a provisional patent application for the delivery technology. The stock was rallying by 79.72% to $3.90 in Thursday's premarket session. Vanda Ties Up With the University of Illinois For COVID-19 Drug Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced a research partnership with the University of Illinois at Chicago for the investigation of small molecules for treating COVID-19.The company said the collaboration will also cover the use of high-throughput screening assay to identify small molecules that may prevent cathepsin-L cleavage of SARS-CoV-2 glycoproteins that are required for viral processing in the host cell.Vanda shares were up 2.75% at $11.20 at the time of publication.Milestone Scientific Plans Common Stock, Warrant Offering Milestone Scientific Inc. (NYSE: MLSS) said it intends to sell shares of its common stock and warrants to purchase shares in an underwritten public offering. The company said it plans to use the net proceeds for the manufacturing, marketing and distribution of its CompluFl Epidural System and development of new products and new product uses, working capital and general corporate purposes.View more earnings on IBBThe stock was slipping by 8.6% to 85 cents in the premarket session. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Announcements On COVID-Related Impacts Neuronetics Inc (NASDAQ: STIM) announced preliminary first-quarter revenue of $11.8 million to $12 million, below the $13.77-million consensus estimate. The company also announced withdrawal of its 2020 guidance, citing the uncertainty associated with the COVID-19 pandemic.The company also announced restructuring actions, including a reduction in discretionary expenses and head count. Consequently, the company lowered its operating expenses guidance for 2020.The stock lost 1.69% to $1.74 in after-hours trading.Anika Therapeutics Inc (NASDAQ: ANIK) announced initiatives to strengthen its liquidity in light of the COVID-19 pandemic. As part of the initiatives, the company said it is drawing down $50 million from its existing credit facility. Following the drawdown, the company said it will have total liquidity of about $140 million.The company said it is also exploring other sources of funding aimed at further supporting its liquidity profile, as well as maintaining business and organizational continuity.The stock fell 2.52% to $30.13 in after-hours trading.Organogenesis Holdings Inc (NASDAQ: ORGO) announced preliminary first-quarter results, expecting net revenue of $61 million to $61.6 million, ahead of the $60.62-million consensus estimate. The company also withdrew its 2020 guidance.The stock rose 0.93% to $3.25 in after-hours trading.CareDx Inc (NASDAQ: CDNA) announced preliminary first-quarter revenue of $38.3 million, up 47% year-over-year and ahead of the $37.76-million consensus estimate. The company also withdrew its guidance for 2020.On The Radar Earnings * PAVmed Inc (NASDAQ: PAVM) (after the close) * Related Link: Co-Diagnostics COVID-19 Test Gets FDA Emergency Use Authorization See more from Benzinga * The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO * The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation * The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Bet on these top--ranked stocks with rising P/E to realize outsized gains.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV (NASDAQ: CNTG) * Cue Biopharma Inc (NASDAQ: CUE) * Forty Seven Inc (NASDAQ: FTSV) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Molecular Templates Inc (NASDAQ: MTEM) * Natera Inc (NASDAQ: NTRA) * Ocular Therapeutix Inc (NASDAQ: OCUL) (Piper Sandler lifted the price target for the shares from $7 to $11) * Quest Diagnostics Inc (NYSE: DGX) (announced plans to launch a COVID-19 test service) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech stocks that hit 52-week lows March 5.) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP) * Aytu Bioscience Inc (NASDAQ: AYTU) * Celcuity Inc (NASDAQ: CELC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN) * EXACT Sciences Corporation (NASDAQ: EXAS) * Glaukos Corp (NYSE: GKOS) * Lantheus Holdings Inc (NASDAQ: LNTH) * Mylan NV (NASDAQ: MYL) * Neurometrix Inc (NASDAQ: NURO) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG) (went public last week) * Polarityte Inc (NASDAQ: PTE) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * SurModics, Inc. (NASDAQ: SRDX) (reacted to first-quarter results) * T2 Biosystems Inc (NASDAQ: TTOO) * Xeris Pharmaceuticals Inc (NASDAQ: XERS)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus AstraZeneca's Imfinzi Flunks Late-Stage Study In Advanced Bladder Cancer AstraZeneca plc (NYSE: AZN) said a late stage trial that evaluated Imfinzi and Imfinzi plus tremelimumab in unresectable, Stage IV bladder cancer did not meet the primary endpoints of improving overall survival versus standard-of-care chemotherapy for Imfinzi monotherapy in patients whose tumor cells and/or tumor-infiltrating immune cells express high levels of PD-L1, or for Imfinzi plus tremelimumab in patients regardless of their PD-L1 expression.In premarket trading, the shares were slipping 1.65% to $47.58.AbbVie Gets Label Expansion For Shorter-Duration Maviret Course In Hepatitis C AbbVie Inc (NYSE: ABBV) said the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 weeks to eight weeks in treatment-naive, compensated cirrhotic, chronic hepatitis C patients with genotype 3 infection."A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," Janet Hammond, vice president of generic medicines and the virology therapeutic area at AbbVie, said in a statement. Maviret is a collaboration with Enanta Pharmaceuticals Inc (NASDAQ: ENTA).Neuronetics System Receives Breakthrough Device Designation Neuronetics Inc (NASDAQ: STIM) said the FDA granted Breakthrough Device Designation for its NeuroStar Advanced Therapy System for the treatment of bipolar depression.NeuroStar Advanced Therapy, according to the company, is the market leader in transcranial magnetic stimulation, a non-invasive form of neuromodulation, and has been approved for unipolar major depression.The stock was trading 40.22% higher at $3.80 at the time of publication in Friday's premarket session. Silk Road Medical Shares Uplist To Nasdaq Global Select Market Silk Road Medical Inc (NASDAQ: SILK) said its common stock has been approved for uplisting to the Nasdaq Global Select Market and will continue to trade under its current ticker symbol, "SILK." The company went public in April 2019.Earnings Oncology-focused biopharma Arcus Biosciences' fourth-quarter revenue rose from $1.6 million in 2018 to $9.8 million in 2019. The net loss per share widened from 28 cents to 38 cents, which was narrower than the consensus loss estimate of 51 cents per share. Cash, cash equivalents and investments in marketable securities stood at $188.3 million as of Dec. 31, 2019 compared with $259.7 million as of Dec. 31, 2018.In premarket trading Friday, Arcus shares were rising 4.06% to $20.View more earnings on IBBEnzo Biochem, Inc.'s (NYSE: ENZ) fiscal second-quarter revenue edged up from $19.3 million in 2019 to $19.4 million in 2020. The non-GAAP loss narrowed from 18 cents per share to 12 cents per share.The shares were ripping 50.44% higher to $3.40 in Friday's premarket session. Eton Pharmaceuticals Inc (NASDAQ: ETON) reported revenue of $500,000 and a loss of 15 cents per share for the fourth quarter of 2019 versus no revenue and a loss of $2.24 per share one year ago.Eton shares were advancing 6.12% to $5.90 in premarket trading Friday.BioNano Genomics Inc (NASDAQ: BNGO) reported a decline in its fourth-quarter revenue from $4 million in 2018 to $2.8 million in 2019. The net loss widened from $6.41 million to $7.9 million. As of Dec. 31, 2019, the company had cash and cash equivalents of $17.3 million compared to $16.5 million at the end of fiscal year 2018.In premarket trading Friday, BioNano shares were down 24.78% at 85 cents.On The Radar Earnings * Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open) * Digirad Corporation (NASDAQ: DRAD) (before the market open) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) (before the market open)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors See more from Benzinga * The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

"The company has taken steps to significantly reduce operating expenses and maintain the strength of our balance sheet."

Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that its 2020 Annual Meeting of Stockholders will be held solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health and wellbeing of our employees, stockholders and directors. To attend and participate in the virtual Annual Meeting of Stockholders, stockholders of record will need to visit www.virtualshareholdermeeting.com/STIM2020 and use their 16-digit control number (the “Control Number”) received in their notice to log in to this website.

Neuronetics (STIM) delivered earnings and revenue surprises of 8.89% and 2.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?